Cingulate (CING)

• Market cap: $64.8M
• 1 day: -0.41%
• 5 days: -1.43%
• 1 month: 0.63%
• 3 months: -28.32%
• 6 months: 19.06%
• Year to date: 9.82%
• 1 year: 17.89%
• 5 years: -99.55%
• 10 years: -99.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Employees: 14